AYA.AX A$3.29 pre-market 26 Feb 2026: Artrya AI gains and outlook
AYA.AX stock trades at A$3.29 in pre-market on 26 Feb 2026 following a 5.45% uptick from yesterday’s close. Artrya Limited (AYA.AX) remains an AI-focused healthcare software developer on the ASX. Investors reacted to recent updates and underlying technicals, pushing volume to 392,826.00 shares. This note frames the latest AYA.AX stock signals, financial metrics and model forecasts for short and medium horizons.
AYA.AX stock: latest price, liquidity and immediate drivers
Artrya Limited (AYA.AX) opened pre-market at A$3.17 and is trading at A$3.29 on the ASX in Australia. The stock saw 392,826.00 shares change hands versus an average volume of 628,189.00. Key drivers today include post-earnings commentary and renewed interest in AI medical imaging products. One clear short-term input is the 50-day average price of A$3.99, which is acting as resistance.
AYA.AX stock financials and valuation metrics
Artrya reports EPS -0.18 and a negative trailing PE multiple of -17.06. Market capitalisation is A$347,892,400.00 with 113,320,000.00 shares outstanding. The company shows a high price-to-book ratio of 14.86 versus the Healthcare sector average PB of 3.80. Cash per share is 0.11, while the current ratio is 8.27, indicating short-term liquidity buffer. These metrics reflect early-stage revenue and heavy R&D investment.
AYA.AX stock technicals and trading signals
Momentum indicators point to near-term weakness with RSI 35.16, CCI at -105.34 and MACD at -0.22. Bollinger Band middle is A$3.38 and lower band A$2.93, suggesting room for mean reversion. ADX is 29.64, implying a developing trend. Traders should watch a clear break above the A$3.99 50-day average for a bullish confirmation.
Meyka AI grade and AYA.AX stock forecast
Meyka AI rates AYA.AX with a score of 63.21 out of 100 — Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly A$3.09, quarterly A$5.03, and yearly A$7.83 for AYA.AX stock. Compared with the current price of A$3.29, the model implies -6.08% near-term, +52.83% over a quarter and +137.82% over 12 months. Forecasts are model-based projections and not guarantees.
Valuation, price targets and realistic scenarios for AYA.AX stock
Given current metrics and forecasts, a conservative short-term price target is A$3.80 and a 12-month target is A$6.50. A bullish scenario that meets Meyka’s yearly forecast suggests A$7.83 as upside potential. Downside risk includes re-rating toward the year low of A$0.56; a pragmatic stop-loss zone sits near A$1.50. All price targets are model-led and assume no material change in clinical or regulatory outcomes.
Risks, catalysts and sector context for AYA.AX stock
Primary risks include persistent negative earnings, reimbursement delays and slower commercial uptake of Salix imaging software. Artrya faces valuation pressure; price/book is well above Healthcare peers. Catalysts include follow-up commercial contracts, regulatory clearances, and partnerships that scale cloud deployment. The Healthcare sector trends show mixed returns, and Artrya’s AI focus ties its outlook to adoption of AI diagnostic tools.
Final Thoughts
Key takeaways: AYA.AX stock trades at A$3.29 pre-market on 26 Feb 2026 with notable volume and a positive intraday move. Financials show negative EPS (-0.18) and a negative PE, while liquidity metrics remain strong. Technically, RSI 35.16 suggests the stock is near oversold. Meyka AI rates the stock 63.21/100 (Grade B, HOLD) and forecasts A$5.03 at three months and A$7.83 at 12 months, implying +52.83% and +137.82% upside respectively versus the current price. For risk-aware investors the practical short-term target is A$3.80 and a 12-month working target is A$6.50. Use tight risk controls given the company’s negative earnings and rich PB ratio versus sector peers. These views rely on model outputs and public metrics and are informational only. For deeper company filings see Artrya’s site and our Meyka AI stock page for AYA.AX
FAQs
What is the current AYA.AX stock price and volume?
AYA.AX stock is trading at A$3.29 pre-market with 392,826.00 shares traded. Average daily volume is 628,189.00, showing moderate liquidity for intraday moves.
What are Meyka AI’s price forecasts for AYA.AX stock?
Meyka AI’s forecast model projects A$3.09 monthly, A$5.03 quarterly and A$7.83 yearly for AYA.AX stock. These are model-based projections and not guarantees.
What are the main risks to owning AYA.AX stock?
Key risks include continued negative EPS, slow commercial adoption of the Salix AI product, regulatory delays and valuation compression versus Healthcare peers.
How does Artrya’s valuation compare to Healthcare peers?
Artrya’s price-to-book is 14.86, materially above the Healthcare sector average PB of 3.80, reflecting a premium for AI growth but higher re-rating risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.